Tag: event-free survival

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

byJinny Tsangand1 others

September 27, 2024

#VisualAbstract: Temsirolimus Combined with VAC/VI Chemotherapy Did Not Improve Clinical Outcomes of Intermediate-Risk Rhabdomyosarcoma

byJinny Tsangand1 others

July 18, 2024

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

byKathleen Lau

April 8, 2022

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

byKathleen Lau

November 12, 2021

#VisualAbstract Reduced-dose lenalidomide regimen significantly prolongs event-free survival in elderly, intermediate-fit patients with newly diagnosed multiple myeloma

byKathleen Lau

June 11, 2021

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

byKathleen Lau

February 18, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: event-free survival

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

#VisualAbstract: Temsirolimus Combined with VAC/VI Chemotherapy Did Not Improve Clinical Outcomes of Intermediate-Risk Rhabdomyosarcoma

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

#VisualAbstract Reduced-dose lenalidomide regimen significantly prolongs event-free survival in elderly, intermediate-fit patients with newly diagnosed multiple myeloma

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports